Physician profile
Adam E Ammar
NPI 1184002248
$599.80
in general payments reported to CMS, 2019-2025
12 companies · $52.04 in 2025
The $52.04 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $229 · 2023: $42.52 · 2024: $276 · 2025: $52.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $370.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nico Corporation | $229.40 | 2021 | |
| Integra Lifesciences Corporation | $184.82 | 2023-2024 | Duraseal Exact Spinal Sealant System, Codman Hakim, Codman Certas |
| Livanova USA, INC. | $28.91 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $22.29 | 2024 | Briviact |
| Itf Therapeutics LLC | $19.51 | 2024 | |
| Mimedx Group, INC. | $19.19 | 2025 | |
| Azurity Pharmaceuticals, INC. | $17.73 | 2024 | Zonisade |
| Bioventus LLC | $17.02 | 2025 | Bonescalpel & Sonicone (O.R.) |
| Neurocrine Biosciences, INC. | $15.83 | 2025 | |
| Neos Therapeutics, LP | $15.75 | 2024 | Cotempla Xr-Odt |
| Medtronic, INC. | $15.14 | 2024 | Strata |
| Immedica Pharma US, INC. | $14.21 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Ammar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.